Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

To ensure pharmaceutical-grade consistency from a living organism, Kaiko addresses biological variability with stringent controls. This includes using Specific Pathogen-Free (SPF) grade pupae from specialized facilities and collaborating directly with regulatory bodies like Japan's PMDA to establish clear acceptance criteria, aligning the novel platform with pharmaceutical expectations.

Contrary to the belief of those outside manufacturing, establishing a bioprocess is not a one-time task. The inherent unpredictability of biology means things will inevitably go wrong even in the most controlled environments, making it a continuous and difficult challenge.

Unlike manufacturing with clonal cell populations, using individual silkworm pupae introduces inherent biological variability between organisms. This creates a significant and scientifically unsolved quality assurance problem for meeting the strict batch-to-batch consistency required for human injectable drugs at commercial scale.

A drug's manufacturing process is not static. Over a 10-20 year lifecycle, it will inevitably change due to raw material shifts or optimizations. Therefore, continued verification (PV Stage 3) is crucial for actively managing these expected deviations to maintain a state of control, not just for passive monitoring.

Quality Control is more than a compliance function; it's a vantage point for understanding systemic process inefficiencies. By mastering QC workflows—from raw materials to product release—one can gain the deep operational insights needed to lead large-scale process improvements and even redesign entire manufacturing facilities.

The biotech community often accepts batch-to-batch variability as a given. A more effective mindset is to view it as a fundamental process design flaw. This perspective pushes for more robust, controlled processes that eliminate sources of variability, rather than just managing them with workarounds.

A process that seems simple in a development lab is often not viable in a strict GMP manufacturing environment. To create truly manufacturable therapies, process development scientists need direct, hands-on exposure to GMP constraints and workflows to avoid significant rework and delays.

Unlike traditional biologics with consistent inputs, cell therapy success is dictated by the highly variable quality of patient cells. Heavily pretreated patients yield cells that behave unpredictably, meaning a standard process will inevitably produce a variable product. This fundamental challenge is often underestimated in process development.